```markdown
---
title: "NDA 210274 – Complete Response Letters"
product: "Vancomycin Hydrochloride for Injection"
application_number: "NDA 210274"
applicant: "Zhejiang Novus Pharmaceuticals Co. Ltd."
submission_type: "505(b)(2)"
dosage_strengths:
  - 500 mg/vial
  - 1 gram/vial
  - 5 gram/vial
  - 10 gram/vial
facility:
  name: "Zhejiang Novus Pharmaceuticals Co., Ltd."
  fei: "3013567704"
  location: "Zhejiang, China"
correspondence_dates:
  - date: "2018-06-15"
    signatory: "Sumathi Nambiar, MD"
    title: "Director, Division of Anti-Infective Products"
  - date: "2020-11-27"
    signatory: "Sumathi Nambiar, MD"
    title: "Director, Division of Anti-Infectives"
  - date: "2021-08-25"
    signatory: "Dmitri Iarikov, MD, PhD"
    title: "Deputy Director, Division of Anti-Infectives"
contacts:
  - name: "Sheel Shah, PharmD"
    title: "Regulatory Project Manager"
    phone: "240-402-3968"
  - name: "Naseya Minor"
    title: "Regulatory Project Manager"
    phone: "301-796-0756"
enclosures:
  - "Prescribing Information"
---

## Critical Data

- **NDA Number:** 210274  
- **Product Name:** Vancomycin Hydrochloride for Injection  
- **Dosage Strengths:** 500 mg/vial, 1 gram/vial, 5 gram/vial, 10 gram/vial  
- **Application Type:** Section 505(b)(2) of the FD&C Act  
- **Applicant:** Zhejiang Novus Pharmaceuticals Co. Ltd.  
- **Facility FEI Number:** 3013567704 (Zhejiang, China)  
- **Inspection Status:** Objectionable conditions identified; reinspection required  
- **Prescribing Labeling:** Must be submitted in SPL format and follow FDA guidelines  
- **Labeling Changes Required:** Storage temperature adjustment, bulk package statement  
- **Safety Update Requirement:** Submit complete AE data, study exposure, comparisons  
- **Contacts:** Sheel Shah, PharmD (240-402-3968), Naseya Minor (301-796-0756)  
- **Deadline to Resubmit:** Within one year, clearly mark as “RESUBMISSION”  
- **Regulatory References:** 21 CFR 201.56, 201.57, 314.50(d)(5)(vi)(b), 314.110, 314.65  
- **Enclosures:** Content of Labeling

---

# COMPLETE RESPONSE LETTERS  
## NDA 210274 – Vancomycin Hydrochloride for Injection  
Zhejiang Novus Pharmaceuticals Co. Ltd.  
c/o NSF Health Sciences  
2001 Pennsylvania Avenue, NW, Suite 950  
Washington, DC 20006  

---

## Correspondence Dates & FDA Contact

| Date         | FDA Signatory         | Title                                 |
|--------------|------------------------|---------------------------------------|
| 06/15/2018   | Sumathi Nambiar, MD   | Director, Division of Anti-Infective Products |
| 11/27/2020   | Sumathi Nambiar, MD   | Director, Division of Anti-Infectives |
| 08/25/2021   | Dmitri Iarikov, MD, PhD | Deputy Director, Division of Anti-Infectives |

---

## APPLICATION SUMMARY

- NDA 210274  
- Vancomycin Hydrochloride for Injection  
- Dosage strengths: 500 mg/vial, 1 gram/vial, 5 gram/vial, 10 gram/vial  
- Submitted under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act

---

# ISSUES IDENTIFIED

## 1. Facility Inspections

- The FDA observed objectionable conditions during inspections at the manufacturing facility:  
  Zhejiang Novus Pharmaceuticals Co., Ltd. | FEI: 3013567704 | Zhejiang, China  
- FDA requires:
  - Satisfactory resolution of all objectionable conditions.
  - FDA verification before application approval.
- Travel and inspection delays due to COVID-19 may affect scheduling.

**Links referenced:**

- [Resiliency Roadmap for FDA Inspectional Oversight](https://www.fda.gov/media/148197/download)  
- [COVID-19-Related Guidance Documents](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-related-guidance-documents-industry-fda-staff-and-other-stakeholders)

---

## 2. Prescribing Information

- Proposed Prescribing Information (PI) must comply with 21 CFR 201.56(a), (d) and 201.57.

**Resources:**

- [PLR Guidelines](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/LawsActsandRules/ucm084159.htm)  
- [Pregnancy and Lactation Labeling Rule](http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm)

**Include:**

- Draft labeling that addresses FDA-proposed revisions  
- SRPI checklist for formatting  
- Submit content in Structured Product Labeling (SPL) format  
  - [FDA SPL Format Guidance](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm)  
- Submit:
  - Highlighted/marked-up copy with annotations  
  - Clean Word version

---

## 3. Carton and Container Labeling

### Required Revisions:

1. **Storage Statement**  
   - Update on 5 gram/vial label:  
     - From: `Prior to reconstitution, store at 20°C to 25°C (68° to 77°F)…`  
     - To: `Prior to reconstitution, store at 20°C to 25°C (68°F to 77°F)…`

2. **Strength Statements**  
   - Revise to:  
     - `5 g*/Pharmacy Bulk Package`  
     - `10 g*/Pharmacy Bulk Package`

---

## 4. Safety Update (21 CFR 314.50(d)(5)(vi)(b))

Include data from all nonclinical and clinical studies/trials for the drug across all indications, dosage forms, and dose levels.

### Required Elements:

1. Description of significant safety profile changes  
2. Discontinuations due to adverse events:
   - New data formatted as in the original submission  
   - Combined tabulations with original data  
   - Add comparison tables of adverse event (AE) frequencies  
   - For other indications, provide separate AE tables  
3. Retabulation of premature discontinuation reasons  
4. Case report forms and narrative summaries for:
   - Deaths  
   - Trial discontinuations due to AEs  
   - Serious AEs  
5. Data indicating changes in incidence of common, less serious AEs  
6. Updated clinical study/trial exposure data  
7. Worldwide experience summary and usage estimates  
8. English translations of any newly submitted foreign labels

---

## 5. Product Quality

- Portions withheld  
- Additional comments provided but not considered approvability issues

---

## 6. Other Information

- You are required to **resubmit within one year** or take other allowable actions under 21 CFR 314.110  
- Inaction may result in application being **withdrawn under 21 CFR 314.65**  
- Partial responses will not initiate a new review cycle

### Resubmission Requirements:

- Clearly marked: **"RESUBMISSION"** in bold, large font on the cover letter  
- Full response addressing all deficiencies  
- Declare the resubmission as a complete response

### Requests for Meetings:

- If needed, submit a request per:  
  - [FDA Formal Meetings Guidance (March 2015)](http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm437431.pdf)

---

## Contacts:

- **Sheel Shah, PharmD** — Regulatory Project Manager  
  Phone: 240-402-3968  
- **Naseya Minor** — Regulatory Project Manager  
  Phone: 301-796-0756

---

## Enclosures:

- Content of Labeling:
  - Prescribing Information  
```